Identification of GDF15 peptide fragments inhibiting GFRAL receptor signaling

[1]  K. Yea,et al.  GDNF family receptor alpha‐like antagonist antibody alleviates chemotherapy‐induced cachexia in melanoma‐bearing mice , 2023, Journal of cachexia, sarcopenia and muscle.

[2]  P. Emmerson,et al.  Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist. , 2023, Cell metabolism.

[3]  J. Routy,et al.  Coping With Stress: The Mitokine GDF-15 as a Biomarker of COVID-19 Severity , 2022, Frontiers in Immunology.

[4]  Ki Baek Lee,et al.  Body weight regulation via MT1-MMP-mediated cleavage of GFRAL , 2022, Nature Metabolism.

[5]  J. Routy,et al.  GDF15/GFRAL Pathway as a Metabolic Signature for Cachexia in Patients with Cancer , 2021, Journal of Cancer.

[6]  M. Birnbaum,et al.  GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates. , 2020, Cell metabolism.

[7]  Subhash D. Katewa,et al.  Antibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in mice , 2020, Nature Medicine.

[8]  Subhash D. Katewa,et al.  Antibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in mice , 2020, Nature Medicine.

[9]  X. Bai,et al.  Cryo-EM analyses reveal the common mechanism and diversification in the activation of RET by different ligands , 2019, eLife.

[10]  M. Pisani,et al.  GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance , 2019, Cell.

[11]  M. Korc,et al.  Cancer-associated cachexia , 2018, Nature Reviews Disease Primers.

[12]  J. Wojtaszewski,et al.  Exercise increases circulating GDF15 in humans , 2018, Molecular metabolism.

[13]  Hantao Liu,et al.  Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys , 2017, Science Translational Medicine.

[14]  Jie Tang,et al.  Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15 , 2017, Nature.

[15]  Søren B. Padkjær,et al.  GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand , 2017, Nature Medicine.

[16]  T. Cash-Mason,et al.  GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates , 2017, Nature Medicine.

[17]  P. Emmerson,et al.  The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL , 2017, Nature Medicine.

[18]  Hyun Jin Kim,et al.  Growth Differentiation Factor 15 Predicts Chronic Liver Disease Severity , 2016, Gut and liver.

[19]  A. Vigano,et al.  MAP3K11/GDF15 axis is a critical driver of cancer cachexia , 2015, Journal of cachexia, sarcopenia and muscle.

[20]  Richard Nicoletti,et al.  Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients , 2015, Journal of cachexia, sarcopenia and muscle.

[21]  F. López‐Soriano,et al.  Cancer cachexia: understanding the molecular basis , 2014, Nature Reviews Cancer.

[22]  D. Glass,et al.  Cancer cachexia: mediators, signaling, and metabolic pathways. , 2012, Cell metabolism.

[23]  Tiago Rito,et al.  Studying Protein—Protein Interactions Using Peptide Arrays , 2011 .

[24]  Paula Ravasco,et al.  Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.

[25]  S. Rüdiger,et al.  Studying protein-protein interactions using peptide arrays. , 2011, Chemical Society reviews.

[26]  M. Matoulek,et al.  Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. , 2009, European journal of endocrinology.

[27]  P. Ponikowski,et al.  Cachexia: a new definition. , 2008, Clinical nutrition.

[28]  W. D. Fairlie,et al.  Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1 , 2007, Nature Medicine.

[29]  P. Ponikowski,et al.  Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. , 2007, Journal of the American College of Cardiology.

[30]  J. Welsh,et al.  Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  W. D. Fairlie,et al.  The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. , 2000, The Journal of clinical endocrinology and metabolism.

[32]  W. D. Fairlie,et al.  MIC‐1 is a novel TGF‐β superfamily cytokine associated with macrophage activation , 1999, Journal of leukocyte biology.

[33]  M. Soares,et al.  Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. , 1997, Gene.

[34]  W. D. Fairlie,et al.  MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Hromas,et al.  PLAB, a novel placental bone morphogenetic protein. , 1997, Biochimica et biophysica acta.

[36]  The International Consensus , 1992, The Rights of the Child and the Changing Image of Childhood.

[37]  D. Morgan.  A new definition. , 1983, Journal of the American Dental Association.

[38]  W. Dewys.  Pathophysiology of cancer cachexia: current understanding and areas for future research. , 1982, Cancer research.

[39]  上田晃久,et al.  Macrophage inhibitory cytokine‐1(MIC‐1)と糖尿病性腎症の関連について , 2016 .

[40]  J. Carrero,et al.  Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  M. Kunesova,et al.  The influence of very-low-calorie-diet on serum leptin, soluble leptin receptor, adiponectin and resistin levels in obese women. , 2006, Physiological research.